⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311208 | 0.81 | NPC1 (0.35) | — | |
| SCHEMBL73301 | 0.81 | — | — | |
| SCHEMBL27808446 | 0.80 | — | — | |
| SCHEMBL7737261 | 0.77 | NPC1 (0.33) | — | |
| SCHEMBL2975836 | 0.77 | — | — | |
| SCHEMBL24268634 | 0.77 | — | — | |
| SCHEMBL30295324 | 0.77 | ESR1 (0.44) | — | |
| SCHEMBL16019416 | 0.77 | NPC1 (0.33) | — | |
| SCHEMBL550395 | 0.77 | TAAR1 (0.50) | — | |
| SCHEMBL7569836 | 0.77 | CHRM3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| WO-2015037716-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 住友化学株式会社 (JP) | 2015-03-19 | — | — | WO | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| WO-2007006546-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | disclosed |
| US-20060293297-A1 | Cyanofluoropyrrolidine derviative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1627870-A1 | CYANOFLUOROPYRROLIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-5760025-A | ADMINISTERING TESTOSTERONE 5A-REDUCTASE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5717088-A | REACTING WITH A CYANOPHOSPHATE IN THE PRESENCE OF AN ALKALI METAL CYANIDE | SANKYO COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| US-5698720-A | INTERMEDIATES FOR TESTOSTERONE 5-ALPHA-REDUCTASE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0567271-B1 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO CO (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0725074-A2 | Compounds suitable for use as intermediates in the preparation of Androst-3,5-dien-3-carboxy derivatives | SANKYO COMPANY LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
| US-5536714-A | Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-16 | — | — | US | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |